AML patients in the trial who were treated with SENTI-202 experienced complete remission after not responding to prior ...

LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

Researchers have developed a new gene expression atlas to map how abnormal differentiation of hematopoietic cells can lead to acute myeloid leukemia (AML).